The shortage exception that legalized compounded Ozempic, Wegovy, Mounjaro, and Zepbound ended in February 2025. As of April 30, 2026, the FDA has formally proposed permanently closing the door — for both 503A pharmacies and 503B outsourcing facilities. So why are clinics still selling "compounded GLP-1" at a discount? And what should you do if you're currently on it?
The FDA shortage exception that allowed pharmacies to compound Ozempic and Mounjaro expired in spring 2025. As of April 30, 2026, the FDA has proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory path that would have kept large-scale compounding alive.
What's still being sold as "compounded GLP-1" in 2026 is no longer operating under the shortage exception. Some of it falls under narrow 503A "personalization" exemptions (e.g., a documented allergy to an inactive ingredient in the brand-name drug). Most of it is operating in a gray zone the FDA has explicitly signalled it will enforce against. If a clinic is offering compounded semaglutide cheaper than the brand-name list price, that is not the FDA shortage exception talking.
If you're currently on compounded GLP-1, the answer isn't to panic-stop. It's to understand the route you're on, ask your prescriber the right questions, and have a transition plan to brand-name medication on hand — because the regulatory trajectory is one direction.
From early 2022 through late 2024, demand for Ozempic, Wegovy, Mounjaro, and Zepbound massively exceeded what Novo Nordisk and Eli Lilly could manufacture. The FDA placed all four on its drug shortage list. That triggered a specific regulatory pathway:
Under Section 506C of the Federal Food, Drug, and Cosmetic Act, when a drug is on the FDA shortage list, licensed compounding pharmacies (503A pharmacies serving individual patients, and 503B outsourcing facilities producing larger batches) are permitted to compound versions of that drug from bulk active pharmaceutical ingredient. The intent of the exception is humanitarian: a patient should not be denied a medically necessary drug simply because the manufacturer can't keep up.
The compounding industry interpreted the shortage broadly. By 2023, hundreds of telehealth providers and weight-loss clinics were offering "compounded semaglutide" or "compounded tirzepatide" at a fraction of brand-name list price. Some patients were genuinely accessing a medication their insurance wouldn't cover and the manufacturer couldn't supply. Others were paying cash because compounded versions were simply cheaper than the brand-name path.
This was the regulatory landscape until late 2024.
A precise sequence matters here, because clinics still selling "compounded GLP-1" in 2026 are operating in a regulatory environment very different from the one most patients remember from 2023.
The 503B bulks list determination is significant because it represents the FDA's view of whether large-scale compounding of a particular substance ever has a legitimate clinical purpose, separate from a temporary shortage. The FDA's April 2026 proposal effectively says: even if a future shortage arises, GLP-1 compounding shouldn't be a long-term answer. The agency is asking outsourcing facilities to plan around brand-name availability, not as a backup channel.
If you search for "compounded semaglutide" today, you'll find dozens of clinics, telehealth platforms, and med spas still offering it. They are not all selling the same thing. Roughly speaking, what's being sold falls into four buckets:
Some 503B outsourcing facilities produced large batches before the May 2025 enforcement deadline. Those vials have shelf lives, and clinics that bought them in bulk are still working through inventory. This is technically permitted — the drug was lawfully compounded at the time, and dispensing what's already produced isn't itself a violation. But this is a window that closes naturally as inventory runs out.
503A pharmacies can compound a non-shortage drug for an individual patient when the brand-name product cannot meet that patient's specific clinical need. The classic legitimate cases: an allergy to an inactive ingredient in the brand-name drug, a need for a different concentration to support careful dose titration, a need for a preservative-free formulation. This is the legitimate ongoing path, and it's narrow by design. Each prescription requires a documented clinical justification specific to that patient.
The FDA has been explicit that "the brand-name version is more expensive than the patient can afford" is not a clinical need that justifies 503A personalization. Cost is an economic concern, not a clinical one.
A subset of clinics market formulations that combine GLP-1s with a second ingredient (typically vitamin B12 or an amino acid like glycine). The marketing pitch is usually that the additive "helps with side effects" or "improves tolerability." These stacks are a regulatory gray area. If the additive serves no clinical purpose and is included to dress up an otherwise impermissible compound as a "personalized" formulation, the FDA has indicated it will look through the form to the substance. There is no documented clinical evidence that adding B12 or glycine to semaglutide reduces nausea or improves outcomes.
Some clinics — including some sizable telehealth players — are simply continuing to sell "compounded semaglutide" or "compounded tirzepatide" with marketing pages that look essentially identical to what they used during the shortage period. There is no documented per-patient personalization, no shortage exception (the shortage is over), and no legitimate 503B pathway (the bulks list has not approved these substances). This is the bucket the FDA has signalled it will enforce against.
Underneath the regulatory machinery is a patient-safety story. The FDA's 2026 actions have been driven in part by accumulating adverse-event data from the compounded supply chain.
The most common adverse event pattern reported to the FDA was patients self-administering incorrect doses from multidose compounded vials. Brand-name Wegovy and Zepbound ship as pre-measured pens or single-dose vials — you cannot dose wrong. Compounded versions often ship as multi-dose vials that require the patient to draw the correct number of units on an insulin syringe. A single decimal-point error or unit-marking misreading can result in 5× or 10× the intended dose. Some of those errors required hospitalization.
Compounded products produced under 506C shortage exception were not subject to the same identity, purity, and sterility standards as FDA-approved drugs. Most reputable 503A and 503B pharmacies maintained high standards anyway. But "most" isn't all, and the regulatory floor was lower. Reports of compounded GLP-1 vials containing the wrong concentration, the wrong active ingredient, or contamination at the gray-market end of the supply chain are documented in FDA enforcement actions throughout 2024 and 2025.
A separate concern: not all compounded GLP-1 was actually compounded from real semaglutide or tirzepatide. The Partnership for Safe Medicines documented multiple cases where supposed "compounded GLP-1" was found to contain substandard or substituted active ingredient, often sourced from Chinese suppliers without the manufacturing oversight legitimate API requires. This is a distinct issue from "compounding pharmacies legitimately producing the drug" — it's outright counterfeiting using compounding-pharmacy aesthetics as cover.
If you're a patient who started on compounded semaglutide or tirzepatide during the shortage and you're still on it in 2026, the question isn't panic. It's understand your route, and have a transition plan.
Ask your prescriber, in plain words: "Is what I'm taking compounded under a 503A personalization exemption, and if so, what specific clinical need is documented in my chart?" A legitimate compounding prescription will have a documented answer (allergy to an inactive ingredient, need for a different concentration to support titration, etc.). If the answer is uncomfortable to give, or amounts to "the brand-name is more expensive," your supply is operating outside the legitimate post-shortage exception.
Before assuming brand-name medication is unaffordable, check actual pricing. Eli Lilly's Lilly Direct program offers Zepbound vials (rather than auto-injector pens) at substantially lower cash prices than the pen formulation — around $500/month for some doses, versus the ~$1,060 list price for pens. Novo Nordisk runs similar savings programs. Manufacturer coupons, insurance prior authorization, and the new cardiovascular and OSA indications have all expanded coverage paths since 2024. The cash-pay calculus in 2026 is meaningfully different from 2023.
The regulatory trajectory points one direction. Even if the FDA's April 2026 proposal takes time to finalize, the door is closing, not opening. If you're getting genuinely good results and your prescriber has a legitimate 503A justification, that may be a sustainable path. But it is worth being transitioned through your prescriber so you have a brand-name protocol ready to start the day your supply ends.
Three signals that the compounded supply you're on is not what your prescriber says it is:
1. The product arrives without a label identifying the compounding pharmacy by name and address. (Real compounding pharmacies put their identification on every dispensed product. Counterfeit operations don't.)
2. The clinic offers "compounded semaglutide" with no documentation request, no prescriber consult longer than five minutes, and no chart notes. Legitimate 503A compounding requires a real prescriber-patient relationship.
3. The price is dramatically below brand-name even with manufacturer programs (e.g. $150/month for compounded semaglutide). The math has to work somewhere; if the price is a fraction of the cost of legitimate ingredient sourcing plus pharmacy margin, the savings are coming from somewhere that should worry you.
If you discover your compounded supply is from a questionable source and decide to stop, don't stop GLP-1 therapy abruptly without a plan. Rapid discontinuation after weeks or months on these drugs has been associated with significant rebound effects (rapid weight regain, blood-sugar swings in diabetic patients). The right move is a clinician-managed transition to a verified brand-name supply, not a cold stop.
The compounded GLP-1 era was a real test of the 506C shortage exception — and exposed that the exception works well when the drug is genuinely scarce, but is hard to wind down once the entire access ecosystem (clinics, telehealth platforms, patient expectations) has built a business model around it.
The FDA's April 2026 proposal to permanently exclude these substances from the 503B bulks list is, in one reading, a regulator drawing a line: future shortages of any drug should be fixed by accelerating manufacturing, not by spinning up a parallel compounded supply chain that becomes hard to roll back. In another reading, it's a recognition that the patient-safety cost of the parallel chain — the 770+ adverse-event reports, the dosing errors, the counterfeit episodes — outweighs the access benefit.
For consumers, the takeaway is simpler. The legitimate path to GLP-1s in 2026 is brand-name medication through a licensed prescriber and pharmacy, with insurance navigation and manufacturer savings programs as the cost-control levers. Compounded versions still exist, but the regulatory air has thinned, the safety record has accumulated, and the door is closing one quarter at a time.
Every claim on this page traces back to FDA filings, court records, or reporting from credentialed legal and regulatory analysts. Read further:
Read the full side-by-side comparison of Semaglutide, Tirzepatide, and Retatrutide — mechanism, weight loss, safety, cost, and which one fits which goal.
Open the GLP-1 comparison